TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05309642

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: They will receive individualized guidance from a hepatologist on how to choose a healthy diet, to reduce the intake of sweets and saturated fatty acids, increase sources of unsaturated fat, avoid large portions, and to regularly eat 3 meals per day. Each participant will be provided a written summary of the dietary advice.
Study: NCT05330871

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1 Nebulized inhalation for booster groups
Description: Ad5-nCoV-IH, 1 dose 0.1ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2 Nebulized inhalation for booster groups
Description: Ad5-nCoV-IH, 1 dose 0.1ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 Nebulized inhalation for booster groups
Description: Ad5-nCoV-IH, 1 dose 0.1ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 Nebulized inhalation for booster groups
Description: Ad5-nCoV-IH, 1 dose 0.1ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 5 Intramuscular injection for booster groups
Description: Ad5-nCoV-IM, 1 dose 0.3ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 6 Intramuscular injection for booster groups
Description: Ad5-nCoV-IM, 1 dose 0.3ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 7 Intramuscular injection for booster groups
Description: Ad5-nCoV-IM, 1 dose 0.3ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 8 Intramuscular injection for booster groups
Description: ICV, 1 dose 0.5ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 9 Intramuscular injection for booster groups
Description: ICV, 1 dose 0.5ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 10 Intramuscular injection for booster groups
Description: 1 dose 0.5ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 11 Nebulized inhalation for booster groups
Description: Ad5-nCoV-IH, 1 dose 0.1ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 12 Nebulized inhalation for booster groups
Description: Ad5-nCoV-IH, 1 dose 0.1ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13 Nebulized inhalation for booster groups
Description: Ad5-nCoV-IH, 1 dose 0.1ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 14 Nebulized inhalation for booster groups
Description: Ad5-nCoV-IH, 1 dose 0.1ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 15 Intramuscular injection for booster groups
Description: Ad5-nCoV-IM, 1 dose 0.3ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 16 Intramuscular injection for booster groups
Description: Ad5-nCoV-IM, 1 dose 0.3ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 17 Intramuscular injection for booster groups
Description: Ad5-nCoV-IM, 1 dose 0.3ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 18 Intramuscular injection for booster groups
Description: ICV, 1 dose 0.5ml

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 19 Intramuscular injection for booster groups
Description: ICV, 1 dose 0.5ml
Study: NCT06048172

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: In the intervention condition, patients are treated directly after the baseline measurement by Prolonged Exposure in 16 hours of individual therapy. The 16 individual therapy sessions will take place in 1 to 2 sessions per week over a period of 7 to 16 weeks. The individual therapy sessions are videotaped with camera focus on the therapist. Parts of the Prolonged Exposure process (the re-experiencing of the traumatic memory) are recorded on tape, so that the patient can listen to the recording as homework at home. Afterwards, the patients take part in a study diagnostic session.
Study: NCT05725135

Intervention type: DRUG
Intervention: Propofol
Description: Propofol total intravenous anesthesia (TIVA) will be used for induction and maintenance of anesthesia. Propofol will be delivered using automated closed-loop anesthesia delivery system.

Intervention type: DRUG
Intervention: Propofol
Description: Propofol total intravenous anesthesia (TIVA) will be used for induction and maintenance of anesthesia. Propofol will be delivered using automated closed-loop anesthesia delivery system.
Study: NCT06011109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APG-157
Description: The participants will receive APG-157 daily; and continue to receive Bevacizumab as standard of care.
Study: NCT05640180

Intervention type: DRUG
Intervention: Finerenone (Kerendia, BAY94-8862)
Description: Retrospective cohort analysis using randomized clinical trials data.
Study: NCT05330871

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 20 Intramuscular injection for booster groups
Description: ICV, 1 dose 0.5ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 21 Nebulized inhalation for primary groups
Description: Ad5-nCoV-IH, 2 doses 0.1ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 22 Nebulized inhalation for primary groups
Description: Ad5-nCoV-IH, 2 doses 0.1ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 23 Nebulized inhalation for primary groups
Description: Ad5-nCoV-IH, 2 doses 0.1ml

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 24 Nebulized inhalation for primary groups
Description: Ad5-nCoV-IH, 2 doses 0.1ml
Study: NCT06151119

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga FAPI PET/CT
Description: 68Ga FAPI PET/CT

Intervention type: DIAGNOSTIC_TEST
Intervention: 68Ga FAPI PET/CT
Description: 68Ga FAPI PET/CT
Study: NCT05465070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leg heat therapy
Description: A sous vide heating immersion circulator heats up the water inside the water tank to 42ºC. A water pump circulates temperature-regulated water through the trousers.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Control
Description: A sous vide heating immersion circulator heats up the water inside the water tank to 33ºC. A water pump circulates temperature-regulated water through the trousers.
Study: NCT06466525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBT-3627
Description: Synthetic peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBT-3627
Description: Synthetic peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBT-3627
Description: Synthetic peptide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vehicle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Vehicle
Study: NCT05386121

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Given intravenously (1 µg/kg) as part of induction of general anesthesia (GA) added to propofol 2 mg/kg and atracurium 0.5 mg/kg Intraoperatively, intravenous fentanyl 0.5 µg/kg (with a maximum dose of 2 µg/kg) will be administered in response to any increase in hemodynamics by more than 20% of baseline values in response to skin incision or there after throughout surgery (after exclusion of other causes of hemodynamic changes)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Description: Will be given intravenously as a rescue analgesic (0.5 mg/kg with maximal dose 1.5 mg/kg) in both study groups if Children's Hospital Eastern Ontario Pain Scale (CHEOPS) more than 6. Quality of postoperative analgesia will be assessed using CHEOPS pain score at time transfer to PACU, 15, 30 minutes then 1, 2, 4, 6 hours postoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Description: Will be given intravenously as a rescue analgesic (0.5 mg/kg with maximal dose 1.5 mg/kg) in both study groups if Children's Hospital Eastern Ontario Pain Scale (CHEOPS) more than 6. Quality of postoperative analgesia will be assessed using CHEOPS pain score at time transfer to PACU, 15, 30 minutes then 1, 2, 4, 6 hours postoperatively.
Study: NCT06468787

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kosmos Anatomical Object Labeling and View Identification Algorithms
Description: Participants underwent limited ultrasound scanning by both cardiac sonographers and abdominal sonographers. Algorithm's performance on the view identification task and the object labeling task is compared to majority opinion of 5 radiologists.
Study: NCT05792124

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spina area block
Description: After anesthesia and surgical intervention, bilateral ESP passage will be performed with ultrasonography from the T10 level 3 cm lateral to the midline. After cleaning the area with povidone iodine before the block, T10 transverse output will be determined using a linear ultrasound probe. Local anesthetic will be applied to the erector spina with the use of the needle used for peripheral block procedures and transverse access. With the serum treatment from the local anesthesia application, the location of the needle will be correct with the hydrodissection method. After the location of the needle is confirmed, a mixture containing 20 ml of LA and serum will be applied and the same procedure will be repeated in the contralateral. 20 ml of total 40 ml LA is bupivacaine 0.5%, after 20 ml serum content.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrolaminar block
Description: The patient is in the prone position and the high-frequency linear ultrasound transducer is in parasagittal orientation, but the entry point is determined more medial than the ESP block. The needle entry point is 1-1.5 cm lateral to the targeted spinos process. The echogenic needle is advanced until it contacts the lamina in the craniocaudal plane and 0.5-1 for control. By giving cc 0.9 nacl solution, it is observed that the fluid is distributed between the erector spina muscle and the lamina. After the location of the needle is confirmed, a mixture of 20 ml of LA and saline will be applied and the same procedure will be repeated in the contralateral. 20 ml of total 40 ml LA will consist of bupivacaine 0.5% and 20 ml physiological saline.
Study: NCT06367595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: IV magnesium sulfate versus magnesium sulfate to intrathecal hyperbaric bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate
Description: IV magnesium sulfate versus magnesium sulfate to intrathecal hyperbaric bupivacaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium sulfate
Description: IV magnesium sulfate versus magnesium sulfate to intrathecal hyperbaric bupivacaine
Study: NCT05121844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitor Device
Description: Continuous glucose monitoring automatically tracks blood glucose levels, also called blood sugar, throughout the day and night. You can see your glucose level anytime at a glance. You can also review how your glucose changes over a few hours or days to see trends. Seeing glucose levels in real time can help you make more informed decisions throughout the day about how to balance your food and physical activity.
Study: NCT05640180

Intervention type: DRUG
Intervention: Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
Description: Retrospective cohort analysis using United States Optum Electronic Health Records data.

Intervention type: DRUG
Intervention: Sodium-glucose cotransporter-2 inhibitors (SGLT2i)
Description: Retrospective cohort analysis using United States Optum Electronic Health Records data.
Study: NCT05936177

Intervention type: OTHER
Group type: OTHER
Intervention: Patient education
Description: The intervention in this osteoporosis education research will consist of a concise and informative educational session delivered by a physiatrist, utilizing slides prepared based on information from reputable sources such as the International Osteoporosis Foundation website and the World Health Organization (WHO) health education booklet. The session will cover various topics including the definition of osteoporosis, its causes, risks, complications, dietary options, and specific exercise recommendations, with a focus on raising awareness and promoting informed decision-making regarding prevention and treatment options.
Study: NCT05249686

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy + Dry Needling
Description: Dry Needling: This is a minimally invasive procedure where a fine needle or acupuncture needle is inserted into the skin and muscle in order to stimulate myofascial trigger points (MTrP) provoking one to six local twitch responses (LTR).~Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy
Description: Manual Therapy Protocol: Intraoral manual techniques were applied to the musculature of both sides, both masseter and medial pterygoid, consisting of both massage and stretching. Furthermore, a grade I-II in the slack-zone traction was applied in the temporomandibular joint (TMJ).
Study: NCT05670327

Intervention type: OTHER
Intervention: Diaphragmatic ultrasound assessment
Description: TFdi, diaphragmatic dysplacement, NAVA assessment, respiratory paramenters
Study: NCT05231317

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant-based diet
Description: 16 days with all foods provided

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Western diet
Description: 16 days with all foods provided
Study: NCT05843461

Intervention type: OTHER
Intervention: Pulmonary Index of Microcirculatory Resistance
Description: PIMR measurement involves placing a coronary pressure wire in the pulmonary arteries and making pressure/time measurements during maximal flow down the artery. PIMR of the right and left pulmonary arteries will be obtained.

Intervention type: OTHER
Intervention: Pulmonary Index of Microcirculatory Resistance
Description: PIMR measurement involves placing a coronary pressure wire in the pulmonary arteries and making pressure/time measurements during maximal flow down the artery. PIMR of the right and left pulmonary arteries will be obtained.

Intervention type: OTHER
Intervention: Pulmonary Index of Microcirculatory Resistance
Description: PIMR measurement involves placing a coronary pressure wire in the pulmonary arteries and making pressure/time measurements during maximal flow down the artery. PIMR of the right and left pulmonary arteries will be obtained.

Intervention type: OTHER
Intervention: Right Ventricle Index of Microcirculatory Resistance
Description: RV-IMR measurement involves placing a coronary pressure wire in the acute marginal branch of the right coronary artery and making pressure/time measurements during maximal flow down the artery.

Intervention type: OTHER
Intervention: Right Ventricle Index of Microcirculatory Resistance
Description: RV-IMR measurement involves placing a coronary pressure wire in the acute marginal branch of the right coronary artery and making pressure/time measurements during maximal flow down the artery.

Intervention type: OTHER
Intervention: Pulmonary artery OCT
Description: OCT of the pulmonary artery involves advancing an OCT catheter over the pressure wire to image the pulmonary artery. OCT of the right and left pulmonary arteries will be performed.

Intervention type: OTHER
Intervention: Pulmonary artery OCT
Description: OCT of the pulmonary artery involves advancing an OCT catheter over the pressure wire to image the pulmonary artery. OCT of the right and left pulmonary arteries will be performed.
Study: NCT04898478

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Seeking Intervention for Pacific Islanders with Opioid Use Disorders
Description: The investigators will design a culturally grounded treatment seeking intervention for Pacific Islanders with OUDs
Study: NCT05164315

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tailored surgery
Description: Procedure: Tailored surgery based on intraoperative local excision/biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total mesorectal excision (TME)
Description: Procedure: Total mesorectal excision for all allocated patients
Study: NCT05921110

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular nerve group block 0,25%
Description: Used for postoperative anagesia after hip operations under spinal anaesthesia.~Drug: Bupivacaine (Block Drug)~For block performances, 0,25% Bupivacaine will be used at 20 ml volume.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular nerve group block 0,16%
Description: Used for postoperative anagesia after hip operations under spinal anaesthesia.~Drug: Bupivacaine (Block Drug)~For block performances, 0,16% Bupivacaine will be used at 20 ml volume
Study: NCT05253404

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu® AuraOnce™ Disposable Laryngeal Mask
Description: Switching endotracheal tube to laryngeal mask at sevoflurane 2.63-2.97%, Removing endotracheal tube when spontaneously generating tidal volume of \>4ml/kg, EtCO2\<45mmHg, Train of four ratio \>70-90%.
Study: NCT06543485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intramedullary screw fixation of metacarpal fractures
Description: intramedullary screw fixation of metacarpal fractures through limited open approach
Study: NCT04781816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR443122
Description: Pharmaceutical form: Capsule Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Capsule Route of administration: Oral
Study: NCT05930080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKCPT
Description: the randomly assigned subjects took the study drug for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celebrex
Description: the randomly assigned subjects took the study drug for 12 weeks
Study: NCT05736393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Back Exosuit
Description: The device is worn like a backpack. It weighs 6 pounds. Participants will be able to perform movements naturally in the device. A ribbon serves as an external muscle to reduce the load and effort during lifting. As participants bend forward, the device assists the participant by supporting some of their body weight by gently pulling back. As participants stand up, the device assists them by gently pulling their trunk upright. Participants will feel the level of assistance change slightly as they move faster or slower. Participants will use this device during 20-40 minutes of physical therapy exercises during 12 visits over 4-6 weeks. Once it is fit and adjusted to each participant's comfort, the physical therapist will control the level of assistance the device provides similarly to how they would adapt any given exercise. Participants may start with more assistance and wean down over the course of the study.
Study: NCT06173531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: Carbetocin nasal spray 3.2 mg three times daily (TID)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given TID, identical in appearance respective to carbetocin treatment
Study: NCT05528575

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry, cranberry, green tea extract, cocoa
Description: tablet supplements, available readily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GOS, Inulin, RS2
Description: Prebiotic combination, Inulin, GOS and RS2

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: prebiotics and polyphenols
Description: combination of the same prebiotics and polyphenols as above

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: maltodextrin, 10g per day
Study: NCT05613842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper-64 labelled SAR-Bombesin
Description: radiolabeled antagonist analog of bombesin for the diagnosis and treatment of gastrin releasing peptide receptor (GRPR)-positive tumors in adults. The product is Copper-64 labelled SAR-Bombesin (Cu-SAR-BBN). Cu-SAR-BBN uses radioactive forms (radionuclide) of copper, copper-64 (64Cu) to image cancers using Positron Emission Tomography (PET) and then copper-67 (67Cu) for therapy by internal beta radiation. 64Cu-SAR-BBN has 3 basic components; the radionuclide (64Cu), bound via MeCOSar (a bifunctional metal chelator, SAR) to a bombesin analog that targets GRPR.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copper-64 labelled SAR-Bombesin
Description: radiolabeled antagonist analog of bombesin for the diagnosis and treatment of gastrin releasing peptide receptor (GRPR)-positive tumors in adults. The product is Copper-64 labelled SAR-Bombesin (Cu-SAR-BBN). Cu-SAR-BBN uses radioactive forms (radionuclide) of copper, copper-64 (64Cu) to image cancers using Positron Emission Tomography (PET) and then copper-67 (67Cu) for therapy by internal beta radiation. 64Cu-SAR-BBN has 3 basic components; the radionuclide (64Cu), bound via MeCOSar (a bifunctional metal chelator, SAR) to a bombesin analog that targets GRPR.
Study: NCT05501288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Huashi Baidu granule
Description: Patients were given HSBDG the day after randomization, with a dose of 2.5g for age 3 to 6 years, 5 g for age 7 to 12 years, and 10 g for age 13 to 18 years, twice daily for 5 consecutive days.

Intervention type: DRUG
Group type: OTHER
Intervention: compound pholcodine oral solution
Description: Patients were given compound pholcodine oral solution (Bright Future Pharmaceuticals Factory, Hong Kong, CHN) the day after randomization, with a dose of 5 ml for age 3 to 6 years and 10 ml for age 7 to 18 years, three times daily for 5 consecutive days.
Study: NCT05948852

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: metabolic surgery (SADIS and OAGB)
Description: TWO HYPOABSORPTION TECHNIQUES FOR THE TREATMENT OF TYPE III OBESITY (BODY MASS INDEX BETWEEN 45 - 49.9 KG/M2): SINGLE ANASTOMOSE DUODENAL SWITCH (SADI-S) AND SINGLE ANASTOMOSE GASTRIC BY-PASS (OAGBP).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: metabolic surgery (SADIS and OAGB)
Description: TWO HYPOABSORPTION TECHNIQUES FOR THE TREATMENT OF TYPE III OBESITY (BODY MASS INDEX BETWEEN 45 - 49.9 KG/M2): SINGLE ANASTOMOSE DUODENAL SWITCH (SADI-S) AND SINGLE ANASTOMOSE GASTRIC BY-PASS (OAGBP).
Study: NCT04819113

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nimenrix
Description: MenACWY-TT vaccine